E. A. Engels, R. M. Pfeiffer, and J. F. Fraumeni, Spectrum of cancer risk among US solid organ transplant recipients, JAMA, vol.306, p.1891, 2011.

C. M. Vajdic, S. P. Mcdonald, and M. R. Mccredie, Cancer incidence before and after kidney transplantation, JAMA, vol.296, p.2823, 2006.

S. Caillard, F. X. Lamy, and C. Quelen, Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas: PTLD French Registry, Am J Transplant, vol.12, p.682, 2012.

M. Green and M. G. Michaels, Epstein-Barr virus infection and posttransplant lymphoproliferative disorder: EBV and PTLD, Am J Transplant, vol.13, p.41, 2013.
DOI : 10.1111/ajt.12004

G. Opelz, V. Daniel, and C. Naujokat, Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma, Transplantation, vol.88, p.962, 2009.

V. R. Dharnidharka, A. C. Webster, O. M. Martinez, J. K. Preiksaitis, V. Leblond et al., Post-transplant lymphoproliferative disorders, Nat Rev Dis Primer, vol.2, p.15088, 2016.

C. L. Davis, K. L. Harrison, J. P. Mcvicar, P. J. Forg, M. P. Bronner et al., Antiviral prophylaxis and the Epstein Barr virusrelated post-transplant lymphoproliferative disorder, Clin Transplant, vol.9, p.53, 1995.
DOI : 10.1007/bf00838054

I. A. Darenkov, M. A. Marcarelli, and G. P. Basadonna, Reduced incidence of EpsteinBarr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy, Transplantation, vol.64, p.848, 1997.

S. V. Mcdiarmid, S. Jordan, and G. S. Kim, Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients, Transplantation, vol.66, p.1604, 1998.

M. A. Malouf, P. N. Chhajed, P. Hopkins, M. Plit, J. Turner et al., Antiviral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients, J Heart Lung Transplant, vol.21, p.547, 2002.

D. P. Funch, A. M. Walker, G. Schneider, N. J. Ziyadeh, and M. D. Pescovitz, Ganciclovir and acyclovir reduce the risk of posttransplant lymphoproliferative disorder in renal transplant recipients: anti-virals reduce risk of PTLD, Am J Transplant, vol.5, p.2894, 2005.

G. Opelz, V. Daniel, C. Naujokat, and H. Fickenscher, Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant nonHodgkin lymphoma: a multicentre retrospective analysis, Lancet Oncol, vol.8, p.212, 2007.

E. Gershburg, M. Marschall, K. Hong, and J. S. Pagano, Expression and localization of the Epstein-Barr virus-encoded protein kinase, J Virol, vol.78, p.12140, 2004.

D. W. Hanto, G. Frizzera, and K. J. Gajl-peczalska, Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation, N Engl J Med, vol.306, p.913, 1982.

C. Bressollette-bodin, M. Coste-burel, B. Besse, E. Andr-e-garnier, V. Ferre et al., Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy, J Med Virol, vol.81, p.90, 2009.

B. Hocker, H. Fickenscher, and H. Delecluse, Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study, Clin Infect Dis, vol.56, p.84, 2013.

S. M. Hosseini-moghaddam, B. Alhomayeed, N. Soliman, M. A. Weir, and A. A. House, Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study, Transpl Infect Dis, vol.18, p.423, 2016.

T. J. Boyle, M. Tamburini, K. R. Berend, A. M. Kizilbash, M. J. Borowitz et al., Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus, Surgery, vol.112, p.378, 1992.

M. Green, J. Reyes, S. Webber, and D. Rowe, The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantation, Transpl Infect Dis, vol.3, p.97, 2001.

B. H?-ocker, S. B?-ohm, and H. Fickenscher, Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation: (Val-) Ganciclovir reduces EBV primary infection, Transpl Int, vol.25, p.723, 2012.

S. I. Martin, B. Dodson, C. Wheeler, J. Davis, T. Pesavento et al., Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients: preventing PTLD in EBV mismatch transplants, Am J Transplant, vol.11, p.1058, 2011.

M. A. Aldabbagh, M. R. Gitman, D. Kumar, A. Humar, C. Rotstein et al., The role of antiviral prophylaxis for the prevention of Epstein-Barr virusassociated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review, Am J Transplant, vol.17, p.770, 2017.

J. M. Kim, S. Lee, and S. J. Kim, Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia, Transplant Proc, vol.42, p.895, 2010.

R. D. Holmes, K. Orban-eller, F. R. Karrer, D. T. Rowe, M. R. Narkewicz et al., Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome, Transplantation, vol.74, p.367, 2002.

D. L. Kogan, M. Burroughs, and S. Emre, Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients, Transplantation, vol.67, p.1068, 1999.

F. Ozc-ßay, H. Arslan, B. Bilezikc-ßi, . Sevmis-ß-s, G. Moray et al., The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients, Transplant Proc, vol.41, p.2878, 2009.

J. Y. Wong, B. Tait, and B. Levvey, Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease, Transplantation, vol.78, p.205, 2004.

S. D. Zangwill, D. T. Hsu, and M. R. Kichuk, Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients, J Heart Lung Transplant, vol.17, p.1161, 1998.

V. R. Dharnidharka, K. E. Lamb, J. A. Gregg, and H. Meier-kriesche, Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States, Am J Transplant, vol.12, p.976, 2012.

D. A. Thorley-lawson and A. Gross, Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N Engl J Med, vol.350, p.1328, 2004.

G. K. Hong, M. L. Gulley, W. Feng, H. Delecluse, E. Holley-guthrie et al., Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model, J Virol, vol.79, p.13993, 2005.

S. Ma, S. Hegde, and K. H. Young, A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas, J Virol, vol.85, p.165, 2011.

C. B. Whitehurst, G. Li, S. A. Montgomery, N. D. Montgomery, L. Su et al., Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice, MBio, vol.6, p.1574, 2015.

B. Gonzalez-farre, J. Rovira, and D. Martinez, In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset posttransplant lymphoproliferative disorders with prognostic implications, Mod Pathol, vol.27, p.1599, 2014.

R. C. Walker, W. F. Marshall, and J. G. Strickler, Pretransplantation assessment of the risk of lymphoproliferative disorder, Clin Infect Dis, vol.20, p.1346, 1995.

R. Mañez, M. C. Breinig, and P. Linden, Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease, J Infect Dis, vol.176, p.1462, 1997.

J. Concato, P. Peduzzi, T. R. Holford, and A. R. Feinstein, Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy, J Clin Epidemiol, vol.48, p.1495, 1995.

E. Vittinghoff and C. E. Mcculloch, Relaxing the rule of ten events per variable in logistic and Cox regression, Am J Epidemiol, vol.165, p.710, 2007.